San Diego-based biotechnology company Cidara Therapeutics Inc. focuses on the development and commercialisation of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology within the United States. The firm's leading product candidate is the innovative rezafungin acetate, from the novel molecule echinocandin class, which provides a promising treatment option for invasive fungal infections, such as candidemia and invasive candidiasis. These infections are associated with elevated mortality rates. Cidara Therapeutics also concentrates on its Cloudbreak platform, creating conjugates for the prevention and treatment of a range of viral infections, including RSV, HIV, and the various SARS-CoV-2 strains causing COVID-19. The company was initially established in 2012 as K2 Therapeutics Inc. before rebranding to Cidara Therapeutics Inc. in July of 2014.